Search

Your search keyword '"Varlet, Pascale"' showing total 464 results

Search Constraints

Start Over You searched for: Author "Varlet, Pascale" Remove constraint Author: "Varlet, Pascale" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
464 results on '"Varlet, Pascale"'

Search Results

1. Supra-tentorial Ependymomas with ZFTA Fusion, YAP1 Fusion, and Astroblastomas, MN1-altered: Characteristic Imaging Features

3. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.

4. Imaging features to distinguish posterior fossa ependymoma subgroups

5. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation

6. PLAG1 fusions extend the spectrum of PLAG(L)-altered CNS tumors

9. CNS neuroblastoma, FOXR2-activated and its mimics: a relevant panel approach for work-up and accurate diagnosis of this rare neoplasm

11. CNS tumor with EP300::BCOR fusion: discussing its prevalence in adult population

12. Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature

17. Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions

19. Apports et limites de la FISH dans le diagnostic des tumeurs du système nerveux central selon la classification de l’OMS de 2021 : retour d’expérience du service de neuropathologie de l’hôpital Sainte-Anne

21. Pediatric spinal pilocytic astrocytomas form a distinct epigenetic subclass from pilocytic astrocytomas of other locations and diffuse leptomeningeal glioneuronal tumours

23. Clinicopathological and molecular characterization of three cases classified by DNA-methylation profiling as “Glioneuronal Tumors, NOS, Subtype A”

25. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

26. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study

28. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients

32. The dural angioleiomyoma harbors frequent GJA4 mutation and a distinct DNA methylation profile

34. Disseminated diffuse midline gliomas, H3K27-altered mimicking diffuse leptomeningeal glioneuronal tumors: a diagnostical challenge!

36. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features

37. A comprehensive histomolecular characterization of meningioangiomatosis: Further evidence for a precursor neoplastic lesion

38. Radiographic growth rate as a predictor of aggressiveness of diffuse gliomas without 1p19q codeletion

40. Atrx loss as a promising screening tool for the identification of diffuse midline glioma subtype, H3K27/MAPKinase co-altered.

41. Diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (DGONC), new name and new problems: an illustration of one case with atypical morphology and biology.

43. Utility of combining OLIG2 and SOX10 IHC expression in CNS tumours: promising biomarkers for subtyping paediatric‐ and adult‐type gliomas

44. CNS erythroblastic sarcoma: a potential emerging pediatric tumor type characterized by NFIA::RUNX1T1/3 fusions

45. LEF-1 immunohistochemistry, a better diagnostic biomarker than β-catenin for medulloblastoma, WNT-activated subtyping

46. “Hemispheric pilocytic astrocytoma” revisited: A comprehensive clinicopathological and molecular series emphasizing their overlap with other glioneuronal tumors

47. BRAIN METASTASIS OF A UROTHELIAL NEUROENDOCRINE CARCINOMA: A DOUBLE PITFALL FOR NEUROPATHOLOGISTS AND DNA‐METHYLATION PROFILING

48. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation

49. Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

50. Supplementary Figures 1-15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

Catalog

Books, media, physical & digital resources